Erythropoiesis News and Research

RSS
3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Acceleron, Celgene to give oral presentations on beta-thalassemia, myelodysplastic syndromes at EHA meeting

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

Akebia completes enrollment in ongoing 200-patient Phase 2b study of AKB-6548

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

NOXXON Pharma reports interim data from two phase IIa studies of anti-CXCL12/SDF-1 Spiegelmer NOX-A12

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

FibroGen presents China-based Phase 2 study data of roxadustat for treatment of CKD patients

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

Cerus enrolls patient in two European clinical trials for INTERCEPT System for RBCs

Whitehead Institute researchers identify drug target for anemia

Whitehead Institute researchers identify drug target for anemia

Two studies shed light on molecular biology of three blood disorders

Two studies shed light on molecular biology of three blood disorders

Researchers find white blood cells produce and eliminate RBCs

Researchers find white blood cells produce and eliminate RBCs

IV iron dextran alternative to oral iron for anemia in nondialysis CKD

IV iron dextran alternative to oral iron for anemia in nondialysis CKD

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

Acceleron commences ACE-536 phase 2 study in beta-thalassemia

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

FDA alerts patients and health care providers of voluntary recall of Omontys by Affymax

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

Acceleron commences ACE-536 phase 2 study in myelodysplastic syndromes

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

NOXXON commences NOX-H94 Phase IIa trial to treat anemia of chronic disease

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

ASN's top five recommendations to avoid wasteful and harmful medical interventions

ASN's top five recommendations to avoid wasteful and harmful medical interventions

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

GeneTex to introduce new antibody against hypoxia-inducible factor 1alpha

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

EC grants marketing authorization for AMAG's ferumoxytol to treat IDA

ASN participates in ABIM Foundation's Choosing Wisely campaign

ASN participates in ABIM Foundation's Choosing Wisely campaign